Adaptive Biotechnologies (ADPT) Operating Leases (2020 - 2026)

Adaptive Biotechnologies (ADPT) has 7 years of Operating Leases data on file, last reported at $69.1 million in Q1 2026.

• Quarterly Operating Leases fell 9.58% year-over-year to $69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (down 9.58% YoY) and the FY2025 annual result came in at $70.2 million, down 11.27% from the prior year.
• Operating Leases eased to $69.1 million in Q1 2026 per ADPT's latest filing, from $70.2 million in the prior quarter.
• The five-year high for Operating Leases was $105.0 million in Q1 2022, with the low at $69.1 million in Q1 2026.
• Average Operating Leases over 5 years is $86.7 million, with a median of $86.9 million recorded in 2024.
• Year-over-year, Operating Leases increased 10.21% in 2022 and slipped 12.04% in 2025.
• Adaptive Biotechnologies' Operating Leases stood at $98.8 million in 2022, then declined by 9.5% to $89.4 million in 2023, then decreased by 11.46% to $79.1 million in 2024, then decreased by 11.27% to $70.2 million in 2025, then slipped by 1.58% to $69.1 million in 2026.
• Business Quant data shows ADPT's Operating Leases at $69.1 million in Q1 2026, $70.2 million in Q4 2025, and $72.4 million in Q3 2025.